Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

What this episode covers

Visit https://www.peervoice.com/CCM860 to view the entire programme with slides. After completing “Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings”, participants will be able to: Explain the mechanistic rationale for investigating the therapeutic potential of TROP2-targeted treatment approaches in early treatment and disease-stage settings for triple-negative breast cancer (TNBC); Differentiate between TROP2-targeted antibody-drug conjugates on construct and mode of action and discuss the potential clinical significance of these differences; and Evaluate the latest clinical data for TROP2-targeted therapeutic strategies in early treatment lines and/or disease-stage settings of TNBC.

Distinct summary based on available episode metadata or transcript content.